Aliases & Classifications for Muscle Hypertrophy

MalaCards integrated aliases for Muscle Hypertrophy:

Name: Muscle Hypertrophy 53 71 28 13
Hypertrophy 41 69
Mslhp 53 71
Myostatin-Related Muscle Hypertrophy 55

Characteristics:

Orphanet epidemiological data:

55
myostatin-related muscle hypertrophy
Inheritance: Autosomal recessive; Age of onset: Infancy,Neonatal;

HPO:

31
muscle hypertrophy:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 53 614160
Orphanet 55 ORPHA275534
UMLS via Orphanet 70 C2931112
SNOMED-CT via HPO 65 258211005
UMLS 69 C0020564

Summaries for Muscle Hypertrophy

UniProtKB/Swiss-Prot : 71 Muscle hypertrophy: A condition characterized by increased muscle bulk and strength. Affected individuals are exceptionally strong.

MalaCards based summary : Muscle Hypertrophy, also known as hypertrophy, is related to hypertrophic cardiomyopathy and myostatin-related muscle hypertrophy, and has symptoms including skeletal muscle hypertrophy, hot flushes and vertigo. An important gene associated with Muscle Hypertrophy is MSTN (Myostatin), and among its related pathways/superpathways are NFAT and Cardiac Hypertrophy and AMP-activated Protein Kinase (AMPK) Signaling. The drugs Acetylcholine and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, smooth muscle and bone, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Wikipedia : 72 Muscle hypertrophy involves an increase in size of skeletal muscle through a growth in size of its... more...

Description from OMIM: 614160

Related Diseases for Muscle Hypertrophy

Diseases related to Muscle Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Related Disease Score Top Affiliating Genes
1 hypertrophic cardiomyopathy 29.4 FHL1 IGF1 MYH6 MYH7
2 myostatin-related muscle hypertrophy 12.5
3 adenoid hypertrophy 12.4
4 masticatory muscles, hypertrophy of 12.2
5 myopathy, x-linked, with postural muscle atrophy 10.9
6 myhre syndrome 10.8
7 muscular dystrophy, congenital, 1b 10.8
8 muscular dystrophy-dystroglycanopathy , type b, 5 10.8
9 central precocious puberty 10.1 IGF1 LEP
10 sleep apnea 10.1 EDN1 IGF1 LEP
11 myosin storage myopathy 10.0 MYH6 MYH7
12 aging 10.0
13 myotonia 9.9
14 familial sick sinus syndrome 9.9 AGT MYH6
15 myotonia congenita 9.9
16 neuropathy 9.9
17 muscular dystrophy 9.9
18 muscular dystrophy, becker type 9.8
19 multifocal motor neuropathy 9.8
20 radiculopathy 9.8
21 hypoplastic left heart syndrome 9.8 LEP MYH6 NPPA
22 malignant hypertension 9.8 AGT EDN1 NPPA
23 autosomal dominant polycystic kidney disease 9.7 AGT EDN1 IGF1 MTOR
24 arteries, anomalies of 9.7 AGT EDN1 LEP
25 aortic valve disease 2 9.7 AGT MYH7 NPPA
26 chronic kidney failure 9.7 AGT EDN1 IGF1 LEP
27 body mass index quantitative trait locus 11 9.6 AGT IGF1 LEP MSTN MTOR
28 blood group, i system 9.6
29 seizures, benign familial neonatal, 1 9.6
30 fibrosis of extraocular muscles, congenital, 1 9.6
31 myositis 9.6
32 myeloma, multiple 9.6
33 muscular dystrophy, duchenne type 9.6
34 esophagitis, eosinophilic, 1 9.6
35 pulmonary hypertension 9.6
36 crohn's disease 9.6
37 spinal muscular atrophy 9.6
38 cardiac arrest 9.6
39 cysticercosis 9.6
40 amyotrophic neuralgia 9.6
41 mononeuropathy 9.6
42 esophagitis 9.6
43 entropion 9.6
44 tarsal tunnel syndrome 9.6
45 hypertrophic pyloric stenosis 9.6
46 pyloric stenosis 9.6
47 vertebrobasilar insufficiency 9.6
48 urethritis 9.6
49 polyneuropathy 9.6
50 mitral valve stenosis 9.6

Graphical network of the top 20 diseases related to Muscle Hypertrophy:



Diseases related to Muscle Hypertrophy

Symptoms & Phenotypes for Muscle Hypertrophy

Clinical features from OMIM:

614160

Human phenotypes related to Muscle Hypertrophy:

31
# Description HPO Frequency HPO Source Accession
1 skeletal muscle hypertrophy 31 HP:0003712

UMLS symptoms related to Muscle Hypertrophy:


hot flushes, vertigo, syncope, signs and symptoms, digestive, signs and symptoms, seizures, icterus, hepatosplenomegaly, headache, fever, edema, dyspnea, cyanosis, cachexia

GenomeRNAi Phenotypes related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.02 IGF1 MTOR
2 Decreased viability with paclitaxel GR00179-A-2 9.02 IGF1 MTOR
3 Decreased viability with paclitaxel GR00179-A-3 9.02 MTOR

MGI Mouse Phenotypes related to Muscle Hypertrophy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.31 MSTN MTOR MYH6 MYH7 NPPA SLC9A1
2 growth/size/body region MP:0005378 10.21 AGT EDN1 FHL1 FOXO1 GATA6 HDAC4
3 behavior/neurological MP:0005386 10.17 AGT FHL1 FOXO1 HDAC4 LEP MEF2A
4 homeostasis/metabolism MP:0005376 10.17 FOXO1 GATA6 IGF1 KLF15 LEP MSTN
5 adipose tissue MP:0005375 10 AGT FOXO1 IGF1 KLF15 LEP MSTN
6 mortality/aging MP:0010768 10 AGT EDN1 FOXO1 GATA6 HDAC4 IGF1
7 muscle MP:0005369 9.89 AGT EDN1 FBXO32 FHL1 FOXO1 GATA6
8 liver/biliary system MP:0005370 9.86 KLF15 LEP MSTN MYH6 SMAD4 AGT
9 renal/urinary system MP:0005367 9.28 NPPA SMAD4 AGT EDN1 IGF1 KLF15

Drugs & Therapeutics for Muscle Hypertrophy

Drugs for Muscle Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 2 51-84-3 187
2
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
3 abobotulinumtoxinA Phase 4,Phase 2
4 Botulinum Toxins Phase 4,Phase 2
5 Botulinum Toxins, Type A Phase 4,Phase 2
6 Cholinergic Agents Phase 4,Phase 2
7 incobotulinumtoxinA Phase 4
8 Neuromuscular Agents Phase 4,Phase 2
9 Neurotransmitter Agents Phase 4,Phase 2
10 onabotulinumtoxinA Phase 4,Phase 2
11 Peripheral Nervous System Agents Phase 4,Phase 2
12 Anesthetics Phase 4
13 Anesthetics, Local Phase 4
14 Anti-Arrhythmia Agents Phase 4
15 Central Nervous System Depressants Phase 4
16 Diuretics, Potassium Sparing Phase 4
17 Sodium Channel Blockers Phase 4
18
Creatine Approved, Investigational, Nutraceutical Phase 3 57-00-1 586
19 Liver Extracts Phase 3
20
Ethanol Approved Phase 2 64-17-5 702
21 insulin Phase 2
22 Insulin, Globin Zinc Phase 2
23 Pharmaceutical Solutions Phase 2
24
Adenosine Approved, Investigational 58-61-7 60961
25
Menthol Approved 2216-51-5 16666
26
Clenbuterol Approved, Investigational, Vet_approved 37148-27-9 2783
27
Terbutaline Approved 23031-25-6 5403
28
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
29
Glycine Approved, Nutraceutical, Vet_approved 56-40-6 750
30 tannic acid Approved, Nutraceutical
31 Adrenergic Agents
32 Adrenergic Agonists
33 Adrenergic beta-2 Receptor Agonists
34 Adrenergic beta-Agonists
35 Albuterol
36 Anti-Asthmatic Agents
37 Autonomic Agents
38 Bronchodilator Agents
39 Respiratory System Agents
40 Tocolytic Agents
41 Caseins
42 Calcium, Dietary
43 Estrogens
44 Hormone Antagonists
45 Hormones
46 Hormones, Hormone Substitutes, and Hormone Antagonists
47 beta-Hydroxy-beta-methylbutyrate Nutraceutical
48 Whey Protein Nutraceutical
49 Linoleate Nutraceutical

Interventional clinical trials:

(show top 50) (show all 52)

# Name Status NCT ID Phase Drugs
1 Xeomin Cosmetic in the Management of Masseter Completed NCT03376464 Phase 4
2 Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques Terminated NCT00992108 Phase 4 lidocaine;chemodenervation
3 Effectiveness of Creatine Supplementation and Exercise on Muscle and Bone Completed NCT01057680 Phase 3
4 Effects of Kneehab 12-week Peri-operative Total Knee Arthroplasty Completed NCT01096524 Phase 3
5 MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy Not yet recruiting NCT03452345 Phase 3 Meditoxin;Placebo
6 Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy Unknown status NCT00260442 Phase 2
7 Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy Completed NCT02010775 Phase 2 Normal saline
8 The Effect of Neuromuscular Electrical Stimulation (NMES) Completed NCT00765739 Phase 2
9 Treatment of Temporo-Myofascial Disorder of Muscular Origin Using Botulinum Toxin: A Prospective Study Not yet recruiting NCT02810015 Phase 2 Botulinum Toxin Type A
10 Exercise and Nutrition Interventions in Age-related Sarcopenia Recruiting NCT02912130 Phase 1
11 Characterization of the Changes in the Signalling Pathways During Spinal Cord Injury-induced Skeletal Muscle Atrophy Unknown status NCT01470950
12 Pascal Pascal Dynamic Contour Tonometer (DCT) Intraocular Pressure and Ocular Pulse Amplitude in Patients With Thyroid Related Orbitopathy: A Comparison to Goldmann Tonometer and to Muscles Characteristics on CT Scan Unknown status NCT00646295
13 Chronic Beta2-adrenergic Stimulation and Cardiac and Skeletal Muscle Hypertrophy Completed NCT02551276 Salbutamol;Placebo
14 Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults Completed NCT02442479
15 Effectiveness of NMES Associated to Vascular Occlusion in Functional Performance and Muscle Hypertrophy in Athlete's Completed NCT02406339
16 The Effects of Lifting Light or Heavy Weights on Muscle Growth and Strength in Trained Young Men Completed NCT02139865
17 The Effect of Insect Protein on Performance and Hypertrophy Completed NCT03034239
18 The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes Completed NCT01508338
19 Post-exercise Recovery After Dietary Protein Ingestion in Healthy Young Men (Meat-Milk Study) Completed NCT01578590
20 Protein Nutrition for Muscle Hypertrophy in Older Adults Completed NCT02315391
21 Comparison of 1 vs 3 Sets of Resistance Training on Muscular Hypertrophy Completed NCT01107691
22 Overeating Different Fats and Influence on Muscle Mass and Body Fat Accumulation Completed NCT02211612
23 Whole Milk Versus Whey Protein Supplement and Resistance Exercise Completed NCT01580189
24 The Use of Neuromuscular Electrical Stimulation to Reverse Muscle Atrophy in Patients With Rheumatoid Arthritis Completed NCT00924625
25 Effects of Native Whey or Milk Supplementation on Adaptations to 12 Weeks of Strength Training in Young and Elderly Completed NCT03033953
26 Protein Supply in Elderly Completed NCT01317511
27 Electrostimulation, Skeletal Muscle Function, and Exercise Capacity in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00874965
28 HIV Posterior Cheek Enlargement Completed NCT01635504
29 Get in Shape in the Team Research: Porukalla Kuntoon Tutkimus Completed NCT02413112
30 Postprandial Muscle Protein Synthesis Following Wheat Protein Ingestion in Vivo in Humans Completed NCT01952639
31 Exercise Intermittent Isometric Handgrip and Blood Flow Restriction Completed NCT02384161
32 Descriptive Study of Knee Joint Pain During Strength Training After Total Knee Arthroplasty Completed NCT01729520
33 Muscle MRI in Becker Muscular Dystrophy and in Limb-girdle Muscular Dystrophy Type 2I Completed NCT02165358
34 High Intensity Interval Training or Strength Training in Women With Polycystic Ovary Syndrome Completed NCT01919281
35 Effective Training in Overweight and Obese People Completed NCT00218920
36 Individual Response to Different Volumes of Resistance Training Completed NCT02179307
37 Skeletal Muscle Hypertrophy and Cardio-Metabolic Benefits After Spinal Cord Injury Recruiting NCT02660073
38 cAMP Signaling and Muscle Adaptations Recruiting NCT02557581 Terbutaline;Clenbuterol;Placebo
39 Blood Flow Restriction Training in Patients With Weight Bearing Restrictions After Knee Surgery Recruiting NCT03371901
40 Low Intensity Resistance Training With Vascular Occlusion in Coronary Heart Disease Patients Recruiting NCT03087292
41 Physical Therapy for Anal Incontinence Recruiting NCT03252951
42 Upper- and Lower-body Resistance Exercise With and Without Blood Flow Restriction on Hemodynamics and Vascular Function Recruiting NCT03225898
43 Activity Dependent Rehabilitation Model to Improve Bone and Muscle Outcomes Recruiting NCT02309983
44 Time-Restricted Feeding Plus Resistance Training in Active Females Recruiting NCT03404271
45 Concurrent Training in Type 2 Diabetes Recruiting NCT03278704
46 Effects of Foot Strengthening on the Incidence of Injuries in Long Distance Runners Recruiting NCT02306148
47 Survey of Patients With Idiopathic Orbital Inflammation Syndrome Active, not recruiting NCT01443000
48 The Anabolic Effects of Estrogen on Skeletal Muscles Not yet recruiting NCT03020953
49 Study of the Reaction of the Brain to Various Stimulations Not yet recruiting NCT03334526
50 The Regulation of Human Skeletal Muscle Mass by Contractile Perturbation Not yet recruiting NCT03046095

Search NIH Clinical Center for Muscle Hypertrophy

Cochrane evidence based reviews: hypertrophy

Genetic Tests for Muscle Hypertrophy

Genetic tests related to Muscle Hypertrophy:

# Genetic test Affiliating Genes
1 Muscle Hypertrophy 28 MSTN

Anatomical Context for Muscle Hypertrophy

MalaCards organs/tissues related to Muscle Hypertrophy:

38
Skeletal Muscle, Smooth Muscle, Bone, Spinal Cord, Heart, Ovary, Prostate

Publications for Muscle Hypertrophy

Articles related to Muscle Hypertrophy:

(show top 50) (show all 183)
# Title Authors Year
1
Akt1 deficiency diminishes skeletal muscle hypertrophy by reducing satellite cell proliferation. ( 29443546 )
2018
2
Calf muscle hypertrophy following S1 radiculopathy: A stress disorder caused by hyperactivity with variable response to treatmen. ( 29451471 )
2018
3
Comment on: Volume for Muscle Hypertrophy and Health Outcomes: The Most Effective Variable in Resistance Training. ( 29396783 )
2018
4
The development of skeletal muscle hypertrophy through resistance training: the role of muscle damage and muscle protein synthesis. ( 29282529 )
2018
5
Incorporation of a skeletal muscle-specific enhancer in the regulatory region of Igf1 upregulates IGF1 expression and induces skeletal muscle hypertrophy. ( 29426944 )
2018
6
Author's Reply to Souza et al: Comment on: "Volume for Muscle Hypertrophy and Health Outcomes: The Most Effective Variable in Resistance Training". ( 29396782 )
2018
7
Recent Perspectives Regarding the Role of Dietary Protein for the Promotion of Muscle Hypertrophy with Resistance Exercise Training. ( 29414855 )
2018
8
Coffee consumption promotes skeletal muscle hypertrophy and myoblast differentiation. ( 29359224 )
2018
9
I^-Secretase Inhibition Induces Muscle Hypertrophy in a Notch-Independent Mechanism. ( 29280566 )
2018
10
Effects of contraction mode and stimulation frequency on electrical stimulation-induced skeletal muscle hypertrophy. ( 29074713 )
2018
11
The role of hormones in muscle hypertrophy. ( 29172848 )
2018
12
A mathematical model of the effects of resistance exercise-induced muscle hypertrophy on body composition. ( 29256047 )
2018
13
lncRNA Chronos is an aging-induced inhibitor of muscle hypertrophy. ( 28855249 )
2017
14
Do metabolites that are produced during resistance exercise enhance muscle hypertrophy? ( 28776271 )
2017
15
Effects of Light-Emitting Diode Therapy on Muscle Hypertrophy, Gene Expression, Performance, Damage, and Delayed-Onset Muscle Soreness: A Case-Control Study With a Pair of Identical Twins. ( 28665818 )
2017
16
Comparative Proteomic and Transcriptomic Analysis of Follistatin-Induced Skeletal Muscle Hypertrophy. ( 28810121 )
2017
17
Teaching Video NeuroImages: Trapezius muscle hypertrophy in multifocal motor neuropathy. ( 28808176 )
2017
18
Myotonia in a Child with Muscle Hypertrophy. ( 28141569 )
2017
19
Muscle hypertrophy and pseudohypertrophy. ( 28778933 )
2017
20
IGF1 stimulates greater muscle hypertrophy in the absence of myostatin in male mice. ( 28533420 )
2017
21
Moderate Intensity Cycling Exercise after Upper Extremity Resistance Training Interferes Response to Muscle Hypertrophy but Not Strength Gains. ( 28912657 )
2017
22
Reply to the Letter to the Editor on "Effects of Light-Emitting Diode Therapy on Muscle Hypertrophy, Gene Expression, Performance, Damage, and Delayed-Onset Muscle Soreness: Case-Control Study With a Pair of Identical Twins". ( 28644245 )
2017
23
Creatine supplementation elicits greater muscle hypertrophy in upper than lower limbs and trunk in resistance-trained men. ( 29214923 )
2017
24
Strength Training with Repetitions to Failure does not Provide Additional Strength and Muscle Hypertrophy Gains in Young Women. ( 28713535 )
2017
25
Myogenic Progenitor Cells Control Extracellular Matrix Production by Fibroblasts during Skeletal Muscle Hypertrophy. ( 27840022 )
2017
26
Can low-load blood-flow restriction training elicit muscle hypertrophy with modest inflammation and cellular stress, but minimal muscle damage? ( 28949007 )
2017
27
The effects of short versus long inter-set rest intervals in resistance training on measures of muscle hypertrophy: A systematic review. ( 28641044 )
2017
28
Satellite Cells Contribution to Exercise Mediated Muscle Hypertrophy and Repair. ( 28042532 )
2017
29
Overload-mediated skeletal muscle hypertrophy is not impaired by loss of myofiber STAT3. ( 28659288 )
2017
30
Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. ( 29109273 )
2017
31
New Management in Bilateral Masseter Muscle Hypertrophy. ( 29109846 )
2017
32
Apigenin enhances skeletal muscle hypertrophy and myoblast differentiation by regulating Prmt7. ( 29108230 )
2017
33
Differential requirement for satellite cells during overload-induced muscle hypertrophy in growing versus mature mice. ( 28693603 )
2017
34
Total training load may explain similar strength gains and muscle hypertrophy seen in aged rats submitted to resistance training and anabolic steroids. ( 28817355 )
2017
35
Effects of linear and daily undulating periodized resistance training programs on measures of muscle hypertrophy: a systematic review and meta-analysis. ( 28848690 )
2017
36
An Extremely Rare Condition: Unilateral and Isolated Temporalis Muscle Hypertrophy. ( 28740790 )
2017
37
Glucocorticoid Receptor ChIP-Seq Identifies PLCD1 as a KLF15 Target that Represses Airway Smooth Muscle Hypertrophy. ( 28375666 )
2017
38
Defining the STATus quo in muscle hypertrophy. Focus on "Overload-mediated skeletal muscle hypertrophy is not impaired by loss of myofiber STAT3". ( 28768642 )
2017
39
Irisin is a pro-myogenic factor that induces skeletal muscle hypertrophy and rescues denervation-induced atrophy. ( 29062100 )
2017
40
Comparative Analysis of Muscle Hypertrophy Models Reveals Divergent Gene Transcription Profiles and Points to Translational Regulation of Muscle Growth through Increased mTOR Signaling. ( 29255421 )
2017
41
Muscle Hypertrophy in Pre-Diabetic Men after Sixteen Weeks of Resistance Training. ( 28663372 )
2017
42
Relationship between Dietary Protein or Essential Amino Acid Intake and Training-Induced Muscle Hypertrophy among Older Individuals. ( 29332899 )
2017
43
Significance of isolated papillary muscle hypertrophy: A comparison of left ventricular hypertrophy diagnosed using electrocardiography vs echocardiography. ( 29280520 )
2017
44
Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins. ( 28935884 )
2017
45
Neurogenic muscle hypertrophy in a 12-year-old girl. ( 27449889 )
2016
46
Muscle hypertrophy as the presenting sign in a patient with a complete FHL1 deletion. ( 27409453 )
2016
47
Transcriptional profiling of rat skeletal muscle hypertrophy under restriction of blood flow. ( 27613141 )
2016
48
Letter to the Editor: Can muscle hypertrophy cause entrapment neuropathy? ( 27419828 )
2016
49
AMPKI^3 is dispensable for skeletal muscle hypertrophy induced by functional overload. ( 26758685 )
2016
50
The effects of resistance exercise on cocaine self-administration, muscle hypertrophy, and BDNF expression in the nucleus accumbens. ( 27137405 )
2016

Variations for Muscle Hypertrophy

ClinVar genetic disease variations for Muscle Hypertrophy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MSTN NM_005259.2(MSTN): c.373+5G> A single nucleotide variant Pathogenic rs397515373 GRCh37 Chromosome 2, 190926945: 190926945

Expression for Muscle Hypertrophy

Search GEO for disease gene expression data for Muscle Hypertrophy.

Pathways for Muscle Hypertrophy

Pathways related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.61 AGT EDN1 IGF1 MEF2A MTOR
2
Show member pathways
12.25 FOXO1 HDAC4 IGF1 LEP MTOR
3
Show member pathways
11.96 HDAC4 IGF1 MEF2A MTOR
4
Show member pathways
11.94 FBXO32 FOXO1 IGF1 SMAD4
5 11.82 FOXO1 MTOR MYH6 SLC9A1
6 11.79 HDAC4 MEF2A MTOR SLC9A1 SMAD4
7 11.77 IGF1 MTOR SMAD4
8 11.73 EDN1 FOXO1 SMAD4
9 11.71 FOXO1 MTOR SMAD4
10 11.67 EDN1 IGF1 MTOR NPPA
11 11.6 MYH6 MYH7 SLC9A1
12 11.55 AGT FOXO1 IGF1 KLF15 LEP MEF2A
13 11.51 EDN1 LEP SMAD4
14
Show member pathways
11.37 AGT EDN1 HDAC4 IGF1 MEF2A MTOR
15
Show member pathways
11 EDN1 IGF1 MTOR
16 10.95 FBXO32 IGF1 MSTN MTOR
17 10.84 MYH7 NPPA SMAD4

GO Terms for Muscle Hypertrophy

Cellular components related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.83 AGT EDN1 FBXO32 FHL1 FOXO1 HDAC4
2 sarcomere GO:0030017 9.33 HDAC4 MYH6 MYH7
3 Z disc GO:0030018 8.92 FBXO32 HDAC4 MYH6 MYH7

Biological processes related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 in utero embryonic development GO:0001701 9.95 EDN1 GATA6 MYH6 SMAD4
2 response to hypoxia GO:0001666 9.92 EDN1 LEP NPPA SMAD4
3 negative regulation of cell growth GO:0030308 9.88 AGT FHL1 NPPA SMAD4
4 female pregnancy GO:0007565 9.86 AGT LEP NPPA
5 cellular response to hypoxia GO:0071456 9.86 EDN1 GATA6 MTOR SLC9A1
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.84 AGT IGF1 MTOR
7 muscle organ development GO:0007517 9.84 FHL1 IGF1 MEF2A MSTN
8 positive regulation of transcription, DNA-templated GO:0045893 9.81 AGT FOXO1 GATA6 HDAC4 IGF1 KLF15
9 response to insulin GO:0032868 9.8 FOXO1 LEP MTOR NPPA
10 cardiac muscle contraction GO:0060048 9.78 MTOR MYH6 MYH7
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 AGT EDN1 MTOR
12 regulation of heart rate GO:0002027 9.76 AGT MYH6 MYH7
13 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.76 AGT IGF1 LEP MYOC
14 cellular response to dexamethasone stimulus GO:0071549 9.74 FBXO32 FOXO1 MSTN
15 cellular response to mechanical stimulus GO:0071260 9.72 AGT HDAC4 MTPN NPPA SLC9A1
16 positive regulation of smooth muscle cell proliferation GO:0048661 9.71 EDN1 HDAC4 IGF1 MTOR
17 regulation of stress fiber assembly GO:0051492 9.69 MYOC SLC9A1
18 energy reserve metabolic process GO:0006112 9.69 LEP MTOR
19 cell growth involved in cardiac muscle cell development GO:0061049 9.69 AGT NPPA
20 regulation of blood vessel size GO:0050880 9.69 AGT EDN1 NPPA
21 adult heart development GO:0007512 9.68 MYH6 MYH7
22 positive regulation of renal sodium excretion GO:0035815 9.67 AGT EDN1
23 cellular sodium ion homeostasis GO:0006883 9.67 AGT SLC9A1
24 response to denervation involved in regulation of muscle adaptation GO:0014894 9.66 FBXO32 HDAC4
25 response to transforming growth factor beta GO:0071559 9.66 EDN1 SMAD4
26 artery smooth muscle contraction GO:0014824 9.65 AGT EDN1
27 positive regulation of calcineurin-NFAT signaling cascade GO:0070886 9.65 IGF1 SLC9A1
28 response to muscle stretch GO:0035994 9.65 EDN1 NPPA SLC9A1
29 regulation of blood pressure GO:0008217 9.65 AGT EDN1 LEP MYH6 NPPA
30 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.64 EDN1 IGF1
31 cellular response to cold GO:0070417 9.64 FOXO1 SLC9A1
32 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.63 HDAC4 SLC9A1
33 positive regulation of follicle-stimulating hormone secretion GO:0046881 9.63 LEP SMAD4
34 regulation of brown fat cell differentiation GO:0090335 9.62 LEP MTOR
35 bone mineralization involved in bone maturation GO:0035630 9.61 IGF1 LEP
36 positive regulation of cell growth involved in cardiac muscle cell development GO:0061051 9.61 EDN1 IGF1 MTOR
37 positive regulation of luteinizing hormone secretion GO:0033686 9.59 LEP SMAD4
38 positive regulation of cardiac muscle hypertrophy GO:0010613 9.43 AGT EDN1 IGF1 MEF2A MTPN SLC9A1
39 cardiac muscle hypertrophy in response to stress GO:0014898 9.1 GATA6 HDAC4 KLF15 MYH6 MYH7 NPPA
40 negative regulation of transcription by RNA polymerase II GO:0000122 10.09 EDN1 FOXO1 GATA6 HDAC4 LEP MEF2A
41 negative regulation of apoptotic process GO:0043066 10.08 FOXO1 GATA6 IGF1 LEP SLC9A1
42 positive regulation of cell proliferation GO:0008284 10.07 AGT EDN1 HDAC4 IGF1 LEP
43 positive regulation of transcription by RNA polymerase II GO:0045944 10.02 EDN1 FOXO1 GATA6 HDAC4 IGF1 KLF15
44 regulation of receptor activity GO:0010469 10 AGT EDN1 IGF1 LEP MSTN NPPA

Molecular functions related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.77 GATA6 HDAC4 MEF2A MTOR MYH6
2 transcription regulatory region DNA binding GO:0044212 9.76 GATA6 HDAC4 KLF15 SMAD4
3 chromatin binding GO:0003682 9.72 FOXO1 GATA6 HDAC4 MEF2A SMAD4
4 sequence-specific DNA binding GO:0043565 9.63 FOXO1 GATA6 HDAC4 MEF2A MTPN SMAD4
5 growth factor activity GO:0008083 9.56 AGT IGF1 LEP MSTN
6 actin-dependent ATPase activity GO:0030898 9.48 MYH6 MYH7
7 peptide hormone receptor binding GO:0051428 9.4 LEP NPPA
8 RNA polymerase II transcription factor binding GO:0001085 9.26 GATA6 HDAC4 MEF2A SMAD4
9 hormone activity GO:0005179 9.02 AGT EDN1 IGF1 LEP NPPA
10 protein binding GO:0005515 10.36 AGT EDN1 FBXO32 FHL1 FOXO1 GATA6

Sources for Muscle Hypertrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....